Roundhill Investments Launches GLP-1 and Weight Loss ETF (OZEM)

OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030.

NEW YORK, May 21, 2024 /PRNewswire/ — Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which has began trading on Nasdaq today. . OZEM is the world’s first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs.

“OZEM provides investors with a unique opportunity to effectively access companies leading the charge against the global obesity epidemic,” said Dave Mazza, CEO of Roundhill Investments. “With obesity rates nearly tripling since 1975 and expected to affect more than half the population by 2035, the weight-loss drug market is in its infancy, providing substantial growth potential for pioneering companies in the field. innovation in this area.

The obesity treatment market is expected to witness explosive growth. Goldman Sachs Research predicts that the market could grow more than 16 times its current size to reach $100 billion by 2030.2

The Roundhill GLP-1 & Weight Loss ETF (OZEM) is an actively managed ETF designed to provide exposure to a global portfolio of companies involved in the development of weight loss therapies.

The fund’s main holdings include:

Holdings are subject to change. Data as of 05/20/24.

1 WHO, Global Health Observatory (2022), Ourworldindata.com, 2 Goldman Sachs Global Investment Research; Company data.

About Roundhill Investments

Founded in 2018, Roundhill Investments is an SEC-registered investment advisor focused on innovative exchange-traded funds. Roundhill’s range of ETFs offers unique and differentiated exposures to thematic equities, options income and trading vehicles. Roundhill offers extensive ETF knowledge and experience, as the team has collectively launched over 100+ ETFs, including several first-to-market products.

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus or summary prospectus containing this and other information about the Roundhill ETFs, please call 1-855-561-5728 or visit the website at www.roundhillinvestments.com/etf/OZEM. Read the prospectus or summary prospectus carefully before investing.

Risk for healthcare companies. Health care businesses, such as businesses providing medical and health care goods and services, businesses engaged in the manufacturing of medical equipment, supplies and pharmaceutical products, and the operation of health care facilities health and the provision of managed health care, may be affected by government regulations and government health measures. health care programs, increases or decreases in the cost of medical products and services, and product liability claims, among other factors. Many healthcare companies rely heavily on patent protection, and the expiration of a company’s patent can harm its profitability. Health care companies are also subject to competitive forces that may result in price reductions, may be poorly capitalized and may render their products obsolete.

Risk of pharmaceutical companies. The Fund may have significant exposure to pharmaceutical companies through its investments in GLP-1 and weight loss companies.
Pharmaceutical companies may be affected by industry competition, reliance on a limited number of products, product obsolescence, government approvals and regulations, loss or alteration of proprietary rights intellectual property and product liability disputes. Pharmaceutical products are subject to competitive forces that may make it difficult to increase the prices of their products and result in price reductions. The profitability of some pharmaceutical companies may depend on a relatively limited number of products. The research and development costs required to bring a new product to market are significant, with no guarantee that the product will ever become profitable. Many new products must obtain approval from the United States Food and Drug Administration (“FDA”), which can be time-consuming and costly. Many pharmaceutical companies rely heavily on patents and intellectual property rights. The loss or depreciation of these rights could have an adverse effect on the profitability of these companies. Pharmaceutical companies may also be subject to numerous product liability disputes and similar claims.

Risk for biotechnology companies. The Fund may have significant exposure to biotechnology companies through its investments in GLP-1 and weight loss companies. Biotechnology companies invest heavily in research and development, which does not necessarily result in commercially successful products. Biotechnology companies are subject to increased government regulation that may delay or prevent the commercialization of new products. The effects of high development costs and increased regulation can be exacerbated by a company’s inability to raise prices to cover costs due to pressure from managed care or price controls. Many biotechnology companies depend on their ability to use and enforce intellectual property rights and patents. Any infringement of these rights may have adverse financial consequences. Biotech stocks, especially those issued by smaller, less experienced companies, tend to be more volatile than the broader market. Biotechnology companies can also be significantly affected by technological evolution and obsolescence, product liability lawsuits and resulting high insurance costs.

Concentration risk. The Fund is concentrated in the industry or group of industries that make up the healthcare sector. The Fund may be subject to increased risk of loss, including losses due to adverse events that affect the Fund’s investments more than the market as a whole, to the extent that the Fund’s investments are concentrated in securities and/or or other assets of a particular issuer or issuers, country, group of countries, region, market, industry, industry group, sector, market segment or asset class.

Risk related to new funds. The Fund is a recently established investment company with a limited operating history. As a result, potential investors have a limited track record or track record on which to base their investment decision.

Roundhill Financial Inc. acts as investment advisor. The Funds are distributed by Foreside Fund Services, LLC, which is not affiliated with Roundhill Financial Inc., US Bank or any of their affiliates.

SOURCE Roundhill Investments

Source